Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

[21] Fabbri L(2018)Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD Am J Respir Crit Care Med 198 329-10

[22] Ferguson GT(2009)Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial Am J Respir Crit Care Med 180 741-1929

[23] Rabe KF(2014)Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease N Engl J Med 371 1285-784

[24] Martinez FJ(2016)Withdrawal of inhaled glucocorticoids and exacerbations of COPD COPD 13 1-59

[25] Tonin FS(2017)Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies Lancet 389 1919-24

[26] Rotta I(2016)Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial Bull World Health Organ 94 782-66

[27] Mendes AM(2018)Use of network meta-analysis in clinical guidelines BMJ Evid Based Med 23 56-67

[28] Pontarolo R(2019)Network meta-analysis: the highest level of medical evidence? COPD 16 18-228

[29] Cazzola M(2019)Clinical decision support system: a pragmatic tool to improve acute exacerbation of COPD discharge recommendations Respir Med 158 59-14

[30] Rogliani P(2015)A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol Pulm Pharmacol Ther 31 63-352

[21] Fabbri L(2018)Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD Am J Respir Crit Care Med 198 329-10

[22] Ferguson GT(2009)Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial Am J Respir Crit Care Med 180 741-1929

[23] Rabe KF(2014)Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease N Engl J Med 371 1285-784

[24] Martinez FJ(2016)Withdrawal of inhaled glucocorticoids and exacerbations of COPD COPD 13 1-59

[25] Tonin FS(2017)Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies Lancet 389 1919-24

[26] Rotta I(2016)Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial Bull World Health Organ 94 782-66

[27] Mendes AM(2018)Use of network meta-analysis in clinical guidelines BMJ Evid Based Med 23 56-67

[28] Pontarolo R(2019)Network meta-analysis: the highest level of medical evidence? COPD 16 18-228

[29] Cazzola M(2019)Clinical decision support system: a pragmatic tool to improve acute exacerbation of COPD discharge recommendations Respir Med 158 59-14

[30] Rogliani P(2015)A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol Pulm Pharmacol Ther 31 63-352